Prevention markets patented and clinically proven products which have been tested on humans to demonstrate their claimed health benefits. The Company is developing attractive brands that can serve as a brand platform to related products. Prevention’s management team has over 100 years of collective experience in the management of consumer health product and biopharmaceutical companies and has capitalized on established relationships with physicians and scientists affiliated with Yale University to obtain licenses for Prevention’s technology. Prevention intends to derive revenue from multiple sales channels and multiple product offerings that meet management’s inclusion criteria. All Prevention products must provide a clinically proven benefit to consumers and have patent protection for their formulation and/or use. The Company’s lead brand is OMAX3® The Ultra-Pure Omega-3 Supplement™ a patented, clinically studied superior omega-3 formulation that, as demonstrated by the recent introduction of OMAX3® Eye Health, provides significant opportunity as a brand platform for several product extensions.
The Company is currently marketing OMAX3® The Ultra-Pure Omega-3 Supplement™ and OMAX3® Eye Health™ products and plans to introduce other QMAX3® products in the coming 12 to 18 months. Both current OMAX3® products comprise a patented and uniquely effective ratio of 4 to 1 of EPA (Eicosapentaenoic acid) to DHA (Docosahexaenoic acid), the two most important omega-3 fatty acids, in a pharmaceutical-grade 91% pure formulation. The Company has licensed the intellectual property covering OMAX3® products pursuant to an exclusive license agreement with the Yale University affiliated physicians who developed it. The Company believes that various tests of the OMAX3® formulation in humans and animals demonstrate that it constitutes the optimum omega-3 concentration and EPA:DHA ratio to provide additional health benefits. Both marketed OMAX3® products provide the highest purity and concentration levels of omega-3 fatty acids available on the market.
Management also plans to introduce an OMAX3® skin care product which is likely contain to FloraGLO Lutein, and Vitamin-D, all of which have been shown to beneficial to skin care. Other OMAX3® products are also planned.
Prevention’s management is comprised of several highly experienced executives with extensive expertise in the over-the-counter and dietary supplement, pharmaceutical, and biopharmaceutical sectors.
Mr. Tormey is the President and Chief Executive Officer of the Company and has been in this same role with Prevention since July 1, 2010. Mr. Tormey has more than 35 years of sales and marketing experience in the global pharmaceutical and OTC product markets. From 1976 to 1985, he was Director Sales Staff Management with Johnson & Johnson. From 1985 to 1990, he was A.V.P. Medical/Hospital Sales with Wyeth, (later known as Pfizer). From 1990 to 2003 Mr. Tormey was associated with Nelson Communications Worldwide. In 1990 he joined Professional Detailing Network, as its VP-Sales. Later he served as President of The Medical Phone Company, and finally, President/COO of Nelson Professional Sales (now Publicis Selling Solutions), division of Publicis, S.A., Paris. In 2005 he was Co-Founder & President/COO of LifeGuard Health LLC, (now Physician Recommended Nutraceuticals). From 2006 to 2007, he was Senior Vice-President of Business Development for North America at Innovex, Division of Quintiles Transnational. From 2003 to 2011, he was the Founder/President of The Tormey Consulting Group. Mr. Tormey received his B.S. in Biology from Saint Vincent College, Latrobe, PA, in 1976. Mr. Tormey was chosen to be a director based on his substantial experience working with pharmaceutical and OTC products.
Mr. Piechotta is the Vice President of Marketing of the Company and has served in this role with Prevention since July 1, 2010. Mr. Piechotta has 14 years of experience in the over-the-counter , homeopathic and dietary supplement marketing. From 2006 to 2009, he was Executive Director, Communications and Investor Relations at the Quigley Corporation. From 2000 to 2006, he was Director of Marketing and Communications and from 1998-2000 he was Director of Advertising at the Quigley Corporation. Mr. Piechotta’s over-the-counter product experience includes the marketing and communications efforts for the successful Cold-EEZE® Homeopathic Cold Remedy. He has expertise in retail marketing communications, brand development, direct response advertising, regulatory environments, manufacturing and product design and development. He is currently a candidate for a Masters Degree in Business Administration at St. Joseph’s University. He has an additional Masters Degree in Education focusing on Organization Psychology from Temple University and a B.A in Psychology from Shippensburg University.
Mr. Penner is the Executive Chairman of the Company and has served in this capacity with Prevention since July 1, 2010. Mr. Penner is also the founder of Prevention. Mr. Penner has 34 years of experience in the management of life sciences and large pharmaceutical companies, including 30 years as an officer of such companies, 24 years on Boards of Directors of public and private companies, and 12 years as a founder of life science companies. He has also been an executive officer of publicly traded companies for 15 years, and for 8 years was CEO of a publicly traded Nasdaq company. Among the companies of which he is a co-founder are New Haven Pharmaceuticals, Affinimark Technologies, Rib-X Pharmaceuticals, RxGen, MAK Scientific, Rhei Pharmaceuticals, and Marinus Pharmaceuticals. From 2008 through March 2012, he was the Chairman and CEO of New Haven Pharmaceuticals. Mr. Penner was chosen to be a director of the Company based on this substantial management experience in the pharmaceutical industry and his role as the founder of Prevention.. He currently serves on the Boards of Celldex Therapeutics (Nasdaq: CLDX). Mr. Penner holds a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. in International Law from New York University.
Mr. Kozak is the Vice Chairman of the Board and has served in that role with Prevention since inception. Mr. Kozak is also a founder of the Company. Mr. Kozak has over 20 years of experience in the life sciences and pharmaceutical industries. Since its inception in 2008, he has been an officer and a director of New Haven Pharmaceuticals, Inc., the sub-licensor to Prevention of OTC rights to Yale derived intellectual property related to the Company’s antacid product. From 2006 to 2008, he was Senior Vice President of Commercial Operations at RHEI Pharmaceuticals where he licensed the company’s entire seven product portfolio. From 2002 to 2005, he was Vice President of Business Development of EpiCept Corp., where he was part of the team that acquired Maxim Pharmaceuticals and took EpiCept public and partnered programs with Endo Pharmaceuticals, Inc. and Adolor Corp. From 1999 to 2002 he was Director of Licensing and Corporate Development of Forest Laboratories, Inc. where he created the partnership of Sankyo’s Benicar. From 1997 to 1999, he was Assistant Director of Global Licensing and Corporate Development of Hoffmann-La Roche. From 1989 to 1997 he held various sales and marketing positions, including Assistant Product Manager and Manager of Corporate Licensing and BD at Solvay Pharmaceuticals, launching Lithobid and assisting in the launch of Luvox, and in sales supporting over-the-counter brands Hydrocil® Instant and Balneol®. Mr. Kozak graduated from The University of Connecticut in 1988 with a BS in Marketing. He received his MBA in Marketing and International Business in 1997 from Georgia State University’s Kennesaw State University – Michael J. Coles College of Business Marketing and International Business. Mr. Kozak was chosen to be a director of the Company based on his past experience in the life sciences and pharmaceutical industries and his role as founder of Prevention.
Ms. Bernardi has been nominated to serve as Director of Finance and Controller of the Company and will begin in such capacities upon the closing of the Merger. Ms. Bernardi has over 20 years of accounting and finance experience, including public audit and tax accounting. From January 1998 to September 2005 she was the Controller at Genaissance Pharmaceuticals. From November 2005to June 2008 she served as Controller at Marinus Pharmaceuticals. From June 2008 through2009, she served as Financial Manager at Rib-X Pharmaceuticals.. From July 2009 until February 2010, she worked as an independent consultant. Since February 2010, she has worked at Aetna as Financial Manager. She earned a BS in Accounting from Providence College in 1985 and is a certified public accountant.
Some supplements may contain more than omega-3. And some of that "extra" content you could do without, such as saturated fats, including unwanted omega-6 fatty acids, and toxins like mercury, lead, and PCBs commonly found in fish. Omax3 Ultra-Pure attains exceptional purity through a double distillation process that eliminates these additional substances. All batches are 3rd party tested twice for quality assurance.
Developed by physicians affiliated with Yale University in 2005, we possess research suggesting a significant advantage of a 4:1 ratio of EPA to DHA that allows for the optimal expression of the advantages of both EPA and DHA. This advantage has been demonstrated in pre-clinical and clinical studies across several measures of effectiveness. OMAX3® has significant potential as a mass-marketed omega-3 dietary supplement brand. With its high concentration of omega-3 and its production using cGMP manufacturing standards, OMAX3® has the capacity to increase its market share in the omega-3 supplement marketplace.
A significant advantage of our product is its purity and concentration of omega-3 as compared to other omega-3 products where dose response drives product effectiveness (i.e. a person is required to take substantial dosages of omega-3 to obtain its true benefits). In 2011, the American Heart Association suggested that a person ingest between 1 to 1.5 grams of omega-3 per day. Users of other over-the–counter omega-3 products would need to take substantially more tablets relative to the OMAX3® product in order to achieve a comparable level of effectiveness.
omax3® Eye Health™ was specifically formulated by physicians at Yale University to achieve a balance of EPA and DHA (4:1) that support a proper inflammatory response in the body. This helps reduce the inflammation that can inhibit the production of tears and promote healthy levels of eye moisture. In fact, a study has shown that omax3® Eye Health may promote proper inflammatory responses better than omega-3 supplements with ratios of 1:1 and 7:1.3*
Omega-3 fatty acids and lutein, like those found in omax3® Eye Health, have been shown to:
Prevention is planning several brand extensions to include additional active ingredients added to the OMAX3® patented omega-3 PUFA. These multiple ingredient brand extensions will provide the brand with continued technological superiority. Planned OMAX3® brand extensions include a dermatological extension, a mood health extension, and a maximum dose product version. Depending upon its financial resources, the Company hopes to launch a dermatology product within the next 18 months and other products on a schedule to be determined.
OMAX3® Eye-Health,is a superior formulation over existing products currently recommended by ophthalmologists and optometrists. The product has a higher concentration of omega-3 fatty acids and lutein available for a range of Eye Health issues and is being sold via medical professional sales team into a physician channel that has a mature retail environment driven by eyeglass, contact lenses, eye drop and increasingly dietary supplements sales. The OMAX3® Eye Health product also contains a lutein product (FloraGLO® brand) believed to benefit dry eye. The protective effects of lutein or zeaxanthin contained in OMAX3® Eye Health, were reported to be similar to those of vitamin E (alpha-tocopherol), according to the journal Molecular Vision, dated August 30, 2011.
The study adds to other studies that support the role of lutein and zeaxanthin for eye health, with the majority supporting their role against age-related macular degeneration, the leading cause of legal blindness for people over 55 years of age in the Western world, according to AMD Alliance International Lutein is naturally deposited as a protective layer in the macula, a small spot in the back of the eye responsible for central vision. This layer, known as macular pigment, works like internal sunglasses inside one’s eyes protecting them from damaging light. Healthy macular pigment can improve one’s ability to react to bright flashes of light or see objects against a similar background – critical to driving at night or enjoying outdoor sports. To keep eyes healthy and protect them as they age, research indicates that people need 10 mg of lutein everyday through dietary sources and products containing lutein.
Click Here to go to Omax3 Eye-Health Website.
If you are a healthcare provider and are interested in providing Omax3, the most concentrated and only ultra pure omega-3 available with a 4:1 ratio of EPA:DHA, to your patients, please click here.
If you are interested in receiving more information from the Company regarding its products or business,
including clinical study facts on file, please enter your information below: